SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-287710
Filing Date
2022-11-17
Accepted
2022-11-17 16:35:56
Documents
12
Period of Report
2022-11-10
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d360152d8k.htm   iXBRL 8-K 29262
  Complete submission text file 0001193125-22-287710.txt   155499

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ayla-20221110.xsd EX-101.SCH 2864
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ayla-20221110_lab.xml EX-101.LAB 18671
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ayla-20221110_pre.xml EX-101.PRE 11693
6 EXTRACTED XBRL INSTANCE DOCUMENT d360152d8k_htm.xml XML 3456
Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Filer) CIK: 0001797336 (see all company filings)

IRS No.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39279 | Film No.: 221398918
SIC: 2836 Biological Products, (No Diagnostic Substances)